Medigen Vaccine Biologics Corporation Stock price

Equities

6547

TW0006547003

Pharmaceuticals

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
52.2 TWD -0.38% Intraday chart for Medigen Vaccine Biologics Corporation -1.69% -25.53%
Sales 2024 * - Sales 2025 * - Capitalization 17.09B 546B
Net income 2024 * 119M 3.8B Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * 252M 8.05B Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
144 x
P/E ratio 2025 *
-
Employees 103
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.37%
More Fundamentals * Assessed data
Dynamic Chart
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Medigen Vaccine Biologics Corporation Provides License Covid-19 Vaccine to WHO C-TAP and UN Medicines Patent Pool CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review CI
Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees CI
Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine to Drug Administration of Vietnam CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Medigen Vaccine Biologics Corporation Announces Board Changes CI
Medigen Vaccine Biologics Corporation Announces the Resignation of Chang, Ming-Cheng as Independent Director CI
Medigen Vaccine Biologics Corporation Receives the NDA Approval Letter of Mvcquadrivalent Influenza Vaccine from Taiwan Food and Drug Administration CI
Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 day-0.38%
1 week-1.69%
Current month-14.71%
1 month-14.98%
3 months-25.43%
6 months-28.30%
Current year-25.53%
More quotes
1 week
51.50
Extreme 51.5
54.00
1 month
51.50
Extreme 51.5
61.70
Current year
51.50
Extreme 51.5
70.70
1 year
51.50
Extreme 51.5
81.50
3 years
51.50
Extreme 51.5
281.22
5 years
18.21
Extreme 18.2087
281.22
10 years
16.19
Extreme 16.1855
281.22
More quotes
Managers TitleAgeSince
Chief Executive Officer - 12-12-11
Director of Finance/CFO - 14-08-14
Chairman 81 -
Members of the board TitleAgeSince
Chairman 81 -
Chief Executive Officer - 12-12-11
Director/Board Member 69 15-09-29
More insiders
Date Price Change Volume
24-03-29 52 -0.38% 803,243
24-03-28 52.2 -0.38% 781,860
24-03-27 52.4 +0.77% 974,734
24-03-26 52 -2.80% 1,313,137
24-03-25 53.5 +0.94% 1,151,027

End-of-day quote Taipei Exchange, March 27, 2024

More quotes
Medigen Vaccine Biologics Corporation is a Taiwan-based company principally engaged in the development and manufacturing of vaccines and biological agents. The Company is engaged in the development of cutting edge technologies for cell-based human vaccines production. For vaccine development, the Company has established the manufacturing process for H1N1 and H5N1. Further, it also conducts clinical trials to confirm safety and efficacy of produced vaccines. In addition, the Company is also engaged in biological agents business.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
52 TWD
Average target price
133 TWD
Spread / Average Target
+155.77%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Medigen Vaccine Biologics Corporation - Taipei Exchange